Orchestra BioMed Holdings, Inc.
OBIOOrchestra BioMed is a biomedical innovation company that develops high-impact therapeutic technologies through a unique risk-reward-sharing partnership model with global medical device leaders.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Orchestra BioMed is a biomedical innovation company that develops high-impact therapeutic technologies through a unique risk-reward-sharing partnership model with global medical device leaders. The company focuses on accelerating late-stage clinical product candidates by leveraging the commercial and manufacturing scale of its strategic partners. Its core value proposition lies in reducing the traditional risks of medical device development while maintaining significant revenue-sharing potential.
Orchestra BioMed acts as a specialized innovation engine that partners with dominant market incumbents rather than competing directly with their commercial infrastructure.
Questions, answered.
- What is Orchestra BioMed Holdings, Inc.'s market cap?
- Orchestra BioMed Holdings, Inc. (OBIO) has a market capitalization of $228.7M and trades on NASDAQ.
- Who are Orchestra BioMed Holdings, Inc.'s competitors?
- Orchestra BioMed Holdings, Inc.'s key competitors include Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, and others. These companies compete in similar markets and product categories.
- Who does Orchestra BioMed Holdings, Inc. partner with?
- Orchestra BioMed Holdings, Inc.'s notable partners include Medtronic, Boston Scientific Corporation.
- Where is Orchestra BioMed Holdings, Inc. headquartered?
- Orchestra BioMed Holdings, Inc. is headquartered in United States of America and employs approximately 56 people. It has been publicly traded since 2023.